Fentanyl 1,500 mcg/30 mL syringe, Injection for Intravenous Use, Concentration = 50 mcg/mL, Prese...
FDA Drug Recall #D-0363-2023 — Class III — February 24, 2023
Recall Summary
| Recall Number | D-0363-2023 |
| Classification | Class III — Low risk |
| Date Initiated | February 24, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | SCA Pharmaceuticals |
| Location | Windsor, CT |
| Product Type | Drugs |
| Quantity | 2125 syringes |
Product Description
Fentanyl 1,500 mcg/30 mL syringe, Injection for Intravenous Use, Concentration = 50 mcg/mL, Preservative Free, Rx Only, Single Dose Container, SCA Pharmaceuticals, Windsor CT 06095, NDC# 70004-0200-16.
Reason for Recall
Subpotent Drug
Distribution Pattern
Nationwide in the US.
Lot / Code Information
Lot # 1222043351, exp. date 03/29/2023 1222043387, exp. date 04/05/2023 1222043352, exp. date 04/05/2023 1222043463, exp. date 04/06/2023 1223043922, exp. date 05/04/2023
Other Recalls from SCA Pharmaceuticals
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0945-2023 | Class II | FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% ... | Jul 20, 2023 |
| D-0555-2023 | Class III | Oxytocin 30 units added to 0.9% Sodium Chloride... | Apr 10, 2023 |
| D-0829-2022 | Class II | Norepinephrine 8mg in 0.9% Sodium Chloride 250 ... | Apr 25, 2022 |
| D-0831-2022 | Class II | Vancomycin HCl 1.5 g in 0.9% Sodium Chloride, 5... | Apr 25, 2022 |
| D-0830-2022 | Class II | Fentanyl 2mcg/ml and Bupivacaine 0.125% in 0.9%... | Apr 25, 2022 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.